A proprietary formula developed in Russia has shown to simultaneously help kill cancer cells, build the body's defense system and accelerate the recovery process. Called PriMed, this safe and effective yeast-derived product contains special compounds shown in both preclinical (animal) and clinical (human) studies to rev up the immune system and speed wound healing. One of the most difficult parts of enduring a surgical procedure, especially when associated with cancer, is recovering from the invasive trauma to the body. The immune system and skin tissues must heal properly and resume their natural roles, an adjustment sometimes taking weeks-or even months.

Following is a brief overview of PriMed's amazing effects:

• When treated with PriMed, breast cancer and skin melanoma patients undergoing various phases of therapy showed excellent acceleration of the recovery process, with no side effects.
• Kidney cancer patients given PriMed after surgery showed enhanced recovery of both the immune system and wound-healing process.
• Even when given amounts exceeding 10 to 50 times the recommended dosage, laboratory animals treated with PriMed showed no short-term or long-term toxic effects.
• PriMed does not induce allergic reactions.
• PriMed exhibited ability to increase the immune system's ability to detect and eradicate tumor cells, while leaving healthy cells alone.

Acute (short-term) studies were conducted on mice, rats and dogs to investigate whether PriMed exerted any toxic effects. No abnormalities or changes in blood protein levels, heart activity, enzymatic activity, cholesterol, triglycerides, or other parameters were noted. When PriMed was given to 30 pregnant rats at 50 times the recommended dosage, no differences were noted in offspring when compared to a control group of 30 pregnant rats not given the product. The fetuses were all normal and healthy for their appropriate stage of gestation. In a study performed on 45 male and 90 female rats, it was concluded that reproductive function was not affected through the administration of PriMed at 50 times the normal dosage. After the animal studies were conducted with such great results, the next step was to give PriMed to human subjects.

It is well established that cancer can regain a foothold in the body after a cancer operation because the invasive nature of surgery stresses the body's defenses. After their surgery, PriMed was given to an experimental group of 18 kidney cancer patients, ages 21-52, to gauge its effectiveness in enhancing and protecting immune function. Their immunological response was compared to a control group of 20 non-cancer patients. Each patient in the experimental group received two tablets of PriMed before a meal, three times a day, for 14 days. Immune system investigations were conducted before the treatment, and then seven and 14 days into the treatment. The investigations included monitoring three key components of immune function and the following observations were noted:

• PriMed boosted the anti-inflammatory properties of the immune system and lowered the inflammation response.
• The production of highly active, fully functional antibodies was observed.
• The numbers of white blood cells responsible for engulfing bacteria and viruses increased.
• Immune cells responsible for recognizing abnormal cells and mounting an attack against them increased.
• Patients with kidney cancer who received the two-week PriMed therapy underwent a smoother recovery period after their surgery. Their surgical incisions healed more quickly and post-operative infections were reduced in frequency. The average healing period of those given PriMed was 8.5 days, compared to 12.8 days in the control group.
• Among patients treated with PriMed, elevated liver enzyme levels returned more quickly to normal during the post-operative period.

From results of these human studies, researchers concluded that PriMed positively improves immune system capacities, expedites the wound healing process, and improves recovery of liver function. The next stage of study tested PriMed on cancer patients in various stages of disease development.

A clinical study involving 204 patients with breast cancer or skin melanoma (age range 18-72 years) was conducted to study the effect of PriMed on those who had undergone surgery and those taking a simultaneous combination treatment of chemotherapy, radiation, and hormone therapy. The experimental group consisted of 102 patients (92 women and 10 men). The control group consisted of 102 patients (82 women and 20 men). Of these, 82 had breast cancer at various stages of development, while 20 had skin melanoma. Both groups were receiving similar treatments that included mastectomy, chemotherapy, and radiation in different combinations of therapy.

Key findings in the experimental group taking PriMed included:

• One month after treatment, prior low levels of white blood cells (35 patients) and hemoglobin levels (50 patients) rapidly normalized.
• Sixty patients (58.7%) who took PriMed experienced a reduction in liver enzyme levels, while levels in the control group remained the same. This revealed that the liver function returned to normal much more quickly in the experimental group as compared to those who did not take PriMed.
• There was also an overall reduction of complications following surgery in the experimental group, as compared to the controls.
• This clinical study revealed that PriMed can facilitate recovery during surgical, complex, and combined treatment in breast cancer and skin melanoma. It can also normalize levels of key enzymes, immune cell function, improve wound healing, and reduce toxicity from chemotherapy treatment. None of the patients exhibited any adverse reactions during the process that could be related to PriMed.

This research overwhelmingly indicates that PriMed's formula is:

• Safe with no side effects
• Substantiated through preclinical and clinical studies
• Powerful for inhibiting cancer growth
• Effective for boosting the immune system's capabilities

PriMed also normalizes enzyme levels and other biomarkers, improves wound healing and decreases chances for post-operative infections. PriMed's proven success history makes it an excellent addition to any cancer treatment regimen for improving outcomes and enhancing the comfort and quality of life of the patient.